BioCryst Pharmacy Switch Inflates ORLADEYO Quarter

Initial stocking at the new pharmacy boosted third-quarter sales; BioCryst cautions that quarterly figures may diverge from patient demand.

Share
BioCryst Pharmacy Switch Inflates ORLADEYO Quarter

BioCryst, which makes ORLADEYO, a once-daily pill that prevents attacks of hereditary angioedema, said its new specialty pharmacy's initial stocking added revenue "in the upper teens of millions of dollars" in the third quarter. The boost sits inside a $29.6 million rise in U.S. ORLADEYO revenue, according to the company's 10-Q filed Wednesday.

Why shipments now count as sales

Under the old setup, the previous pharmacy held no inventory before dispensing. The new sole-source pharmacy takes title to ORLADEYO and must keep 7-21 days of it on hand, and BioCryst books revenue when the product transfers to that pharmacy.

As of September 30, inventory at the new pharmacy was at the lower end of that required range. In its earnings release, BioCryst said it expects the inventory level to stay relatively stable over time, and that ORLADEYO revenue outside Europe still grew year over year once the inventory build is removed.

The 10-Q's risk factors carry new language saying quarterly revenue may reflect the pharmacy's inventory and ordering patterns, which "may not reflect underlying patient demand in the early stages of the transition." The prior quarter's filing did not carry that warning.

The quarter in numbers

Total revenue was $180.3 million, up $20.9 million from a year earlier, with ORLADEYO at $174.8 million. The company said the growth in U.S. ORLADEYO also reflected a higher net price and more oral pellets for children, partly offset by fewer capsule shipments. Its earnings release also reported operating profit of $53.3 million and net income of $37.9 million.

The earnings release kept full-year ORLADEYO guidance at $625 million to $645 million and raised total revenue guidance to $715 million to $730 million, from $690 million to $715 million.

A shift in customer concentration

The previous pharmacy accounted for about 53% of third-quarter product sales and the new one for about 43%. In trade receivables, the two held 24% and 68% at September 30, against 84% for the previous pharmacy at year-end.

BioCryst is a rare-disease drugmaker that closed its Birmingham research site this year and is shifting toward external pipeline assets after buying Astria. The stock had a market value of about $2.2 billion as of the report.

The fourth quarter will show how ORLADEYO sales hold once the new pharmacy's inventory stops building.

Sources

More on BioCryst Pharmaceuticals

All BioCryst Pharmaceuticals (BCRX) coverage →